Myocarditis and Inflammatory Cardiomyopathy

2020 ◽  
pp. 551-563
Author(s):  
Yuri Kim ◽  
David M. Dudzinski
Keyword(s):  
Inflammatory Cardiomyopathy

scholarly journals Targeted treatment in viral‐associated inflammatory cardiomyopathy

2021 ◽  
Vol 9 (7) ◽  
Author(s):  
Ahmad Amin ◽  
Sepideh Taghavi ◽  
Maryam Chenaghlou ◽  
Elahe Zare ◽  
Monireh Kamali ◽  
...  
Keyword(s):  
Targeted Treatment ◽  
Inflammatory Cardiomyopathy

scholarly journals The potential role of plasma miR‐155 and miR‐206 as circulatory biomarkers in inflammatory cardiomyopathy

2021 ◽  
Author(s):  
Danilo Obradovic ◽  
Karl‐Philipp Rommel ◽  
Stephan Blazek ◽  
Karin Klingel ◽  
Matthias Gutberlet ◽  
...  
Keyword(s):  
Potential Role ◽  
Inflammatory Cardiomyopathy

scholarly journals Myocardial Inflammation, Sports Practice, and Sudden Cardiac Death: 2021 Update

Medicina ◽  
2021 ◽  
Vol 57 (3) ◽  
pp. 277
Author(s):  
Paolo Compagnucci ◽  
Giovanni Volpato ◽  
Umberto Falanga ◽  
Laura Cipolletta ◽  
Manuel Antonio Conti ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Cardiac Magnetic Resonance ◽  
Sudden Cardiac Death ◽  
Magnetic Resonance ◽  
Cardiac Death ◽  
Current Knowledge ◽  
Myocardial Inflammation ◽  
Resonance Imaging ◽  
Inflammatory Cardiomyopathy ◽  
The Relationship

Myocardial inflammation is an important cause of cardiovascular morbidity and sudden cardiac death in athletes. The relationship between sports practice and myocardial inflammation is complex, and recent data from studies concerning cardiac magnetic resonance imaging and endomyocardial biopsy have substantially added to our understanding of the challenges encountered in the comprehensive care of athletes with myocarditis or inflammatory cardiomyopathy (ICM). In this review, we provide an overview of the current knowledge on the epidemiology, pathophysiology, diagnosis, and treatment of myocarditis, ICM, and myopericarditis/perimyocarditis in athletes, with a special emphasis on arrhythmias, patient-tailored therapies, and sports eligibility issues.

Acute inflammatory cardiomyopathy: apparent neutral prognostic impact of immunosuppressive therapy

2020 ◽  
Vol 22 (7) ◽  
pp. 1280-1282
Author(s):  
Marco Merlo ◽  
Piero Gentile ◽  
Andrea Ballaben ◽  
Jessica Artico ◽  
Matteo Castrichini ◽  
...  
Keyword(s):  
Immunosuppressive Therapy ◽  
Prognostic Impact ◽  
Inflammatory Cardiomyopathy

Role of myocardial inflammation and fibrosis in the development of ventricular arrythmias in patients with inflammatory cardiomyopathy (results of 1-year follow-up)

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
V Kovalenko ◽  
E Nesukay ◽  
S Cherniuk ◽  
R Kirichenko ◽  
A Kozliuk ◽  
...  
Keyword(s):  
Myocardial Fibrosis ◽  
Cardiac Mri ◽  
Inflammatory Process ◽  
Delayed Enhancement ◽  
Myocardial Inflammation ◽  
Inflammatory Cardiomyopathy ◽  
Initial Examination ◽  
Inflammatory Lesions ◽  
Clinical Onset

Abstract Background Myocardial inflammatory and fibrotic changes are the most frequent and significant causes of ventricular rhythm disorders that could result in development of life threatening arrythmias and increase the risk of sudden cardiac death, especially in young patients with inflammatory cardiomyopathy (ICM). The purpose – to estimate association of myocardial inflammation and fibrosis with development of ventricular arrythmias in patients with ICM during 12-months of follow-up. Material and methods The study was performed on 70 patients with ICM, average age was (35,2±2,7) years. Initially all patients had cardiomegaly with reduced left ventricular (LV) ejection fraction - <40% and absolute value of longitudinal global systolic strain <9,0%. By 24-hour ECG monitoring we studied frequency of ventricular premature beats (VPB) and incidence of non-sustained ventricular tachycardia (NSVT) paroxysms. All patients underwent for cardiac MRI with evaluation of early T1- and T2-weighted images for the detection of inflammatory changes and T1-weighted delayed images for detection of myocardial fibrosis. Results of cardiac MRI were estimated by Lake Louise criteria and also we performed quantification of segments involved according to standard 17-segment LV model. Initial examination was carried out within the 1st month from the clinical onset of disease and subsequent evaluation of studied parameters was performed after 12 months of follow-up. Results After 12 months of follow-up average frequency of VPB reduced to (1,42±0,14) % from (2,32±0,27) % on initial examination (p<0,01), similarly reduced the incidence of NSVT paroxysms – to 11,4% after 12 months from 28,6% initially. Mean quantity of LV segments, affected by inflammatory process and characterized by presence of edema and/or hyperemia, reduced to (2,12±0,22) segm. after 12 months of follow up from (6,12±0,71) segm. on the 1st month (p<0,01). Also we observed increase of LV segments amount with the presence of delayed enhancement which indicates myocardial fibrosis – from (2,04±0,21) segm. on initial examination to (4,79±0,38) segm. after 12 months (p<0,01). Using binary regression analysis we defined that initial presence of inflammatory lesions in ≥5,0 LV segments was associated with frequent VPB (≥1,0%) and NSVT paroxysms. Wherein, after 12 months presence of inflammatory lesions had no association with ventricular rhythm disorders but the same relation was observed between the presence of delayed enhancement in ≥4,0 LV segments and frequent VPB (≥1,0%) as also with NSVT paroxysms. Conclusion At the time of clinical onset of inflammatory cardiomyopathy ventricular rhythm disorders (particularly VPB and NSVT paroxysms) were associated with larger quantity of LV segments involved into inflammatory process. After 12 months of follow-up ventricular rhythm disorders were associated predominantly with the presence of fibrotic lesions in several (≥4,0) segments of LV. Funding Acknowledgement Type of funding source: None

Long-term outcome of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy after immunosuppressive therapy

2016 ◽  
Vol 105 (12) ◽  
pp. 1011-1020 ◽  
Author(s):  
Felicitas Escher ◽  
Uwe Kühl ◽  
Dirk Lassner ◽  
Wolfgang Poller ◽  
Dirk Westermann ◽  
...  
Keyword(s):  
Immunosuppressive Therapy ◽  
Inflammatory Cardiomyopathy ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Chronic Myocarditis

scholarly journals Sipuleucel‐T associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database

2021 ◽  
Author(s):  
Melissa Y.Y. Moey ◽  
Rahim A. Jiwani ◽  
Kotaro Takeda ◽  
Karyn Prenshaw ◽  
R. Wayne Kreeger ◽  
...  
Keyword(s):  
Case Report ◽  
Inflammatory Cardiomyopathy ◽  
Pharmacovigilance Database

CXCL16 is a novel diagnostic marker and predictor of mortality in inflammatory cardiomyopathy and heart failure

2014 ◽  
Vol 176 (3) ◽  
pp. 896-903 ◽  
Author(s):  
Oliver Borst ◽  
Malte Schaub ◽  
Britta Walker ◽  
Martina Sauter ◽  
Patrick Muenzer ◽  
...  
Keyword(s):  
Heart Failure ◽  
Diagnostic Marker ◽  
Inflammatory Cardiomyopathy

High leptin and resistin expression in chronic heart failure: adverse outcome in patients with dilated and inflammatory cardiomyopathy

2012 ◽  
Vol 14 (11) ◽  
pp. 1265-1275 ◽  
Author(s):  
Peter Bobbert ◽  
Alexander Jenke ◽  
Thomas Bobbert ◽  
Uwe Kühl ◽  
Ursula Rauch ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Adverse Outcome ◽  
Inflammatory Cardiomyopathy
Sign in / Sign up

Export Citation Format

Share Document